Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
CEO: Frederick Lowery. Company website
Henry Schein, Inc. (HSIC) trades at $84.84, down 0.24% on the day, as of Sep 20, 2026 13:05 UTC.
Henry Schein, Inc. has a market capitalisation of $9.66B, calculated from the live HSIC share price and shares outstanding.
HSIC trades at a trailing P/E of 24.73, from earnings per share of $3.43 over the last twelve months.
Henry Schein, Inc. generated revenue of $13.60B over the trailing twelve months, which puts the stock at 0.71 times sales.
HSIC has traded between $61.94 and $92.18 over the past 52 weeks, and the last price is 8.0% below that high.
Yes. Henry Schein, Inc. keeps 2.96% of revenue as net income over the trailing twelve months.
Wall Street analysts rate HSIC Buy, with an average price target of $92.33, 8.8% above the current price.
Henry Schein, Inc. is classified under the Healthcare sector and the Medical - Distribution industry, and is domiciled in US.
Frederick Lowery is the chief executive of Henry Schein, Inc., which employs 25,000 people.
QFI Terminal shows HSIC with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open HSIC in Terminal See plans